Pasireotid: Eine neue Therapieoption bei Morbus Cushing

Pasireotide: A New Therapeutic Option in the Treatment of Cushing’s Disease. To date, the treatment algorithm for Cushing’s disease has not included any registered pharmaceutical agents. The multireceptor-targeted somatostatin analogue, pasireotide, which is the first medical therapy specifically developed for this condition, received approval in April 2012. Studies assessing the effects of pasireotide show rapid and persistent reductions in ACTH and cortisol levels with clinical improvements in the majority of patients. J Klin Endokrinol Stoffw 2012; 5 (Sonderheft 2): 1–8.